Marksans Pharma 미래 성장

Future 기준 확인 4/6

Marksans Pharma (는) 각각 연간 23.1% 및 16.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 24.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 18.6% 로 예상됩니다.

주요 정보

23.1%

수익 성장률

24.36%

EPS 성장률

Pharmaceuticals 수익 성장	14.9%
매출 성장률	16.4%
향후 자기자본 수익률	18.62%
애널리스트 커버리지	Low
마지막 업데이트	27 Mar 2025

최근 미래 성장 업데이트

Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price

Feb 15

Recent updates

Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price

Feb 15

Is Marksans Pharma Limited (NSE:MARKSANS) Expensive For A Reason? A Look At Its Intrinsic Value

Feb 01

Teva Pharma Facility And US Expansion To Strengthen Future Outlook

Jan 28 Strategic growth in the U.S. market and facility expansion bolster revenue growth, earnings, and profit margins through enhanced capacity and market share.

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Nov 27

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Oct 24

Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Sep 21

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Jul 28

Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Jun 07

Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

May 31

Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Feb 16

Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

Jan 26

We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Dec 02

Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Jun 21

Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Nov 17

This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Sep 16

Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Sep 01

수익 및 매출 성장 예측

NSEI:MARKSANS - 애널리스트의 미래 추정치 및 과거 재무 데이터 (INR Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
3/31/2027	35,709	6,091	4,217	N/A	2
3/31/2026	30,394	4,832	3,200	N/A	2
3/31/2025	26,155	3,883	2,218	N/A	2
12/31/2024	24,744	3,683	N/A	N/A	N/A
9/30/2024	23,787	3,470	520	2,169	N/A
6/30/2024	22,680	3,338	N/A	N/A	N/A
3/31/2024	21,774	3,137	216	2,304	N/A
12/31/2023	21,034	3,164	N/A	N/A	N/A
9/30/2023	19,971	2,965	894	2,528	N/A
6/30/2023	19,184	2,743	N/A	N/A	N/A
3/31/2023	18,521	2,663	1,838	2,374	N/A
12/31/2022	17,842	2,123	N/A	N/A	N/A
9/30/2022	16,670	2,004	972	1,286	N/A
6/30/2022	15,756	1,847	N/A	N/A	N/A
3/31/2022	14,908	1,868	529	993	N/A
12/31/2021	14,069	2,367	N/A	N/A	N/A
9/30/2021	14,026	2,473	883	1,336	N/A
6/30/2021	14,064	2,518	N/A	N/A	N/A
3/31/2021	13,762	2,385	1,322	1,786	N/A
12/31/2020	13,817	2,018	N/A	N/A	N/A
9/30/2020	13,142	1,724	1,839	2,478	N/A
6/30/2020	12,203	1,476	N/A	N/A	N/A
3/31/2020	11,344	1,208	1,734	2,333	N/A
12/31/2019	10,463	879	N/A	N/A	N/A
9/30/2019	9,972	834	66	416	N/A
6/30/2019	10,099	780	N/A	N/A	N/A
3/31/2019	10,001	804	142	274	N/A
12/31/2018	9,523	666	N/A	N/A	N/A
9/30/2018	9,223	582	N/A	N/A	N/A
6/30/2018	9,272	463	N/A	N/A	N/A
3/31/2018	9,127	358	N/A	501	N/A
12/31/2017	8,918	343	N/A	N/A	N/A
9/30/2017	8,949	275	N/A	N/A	N/A
6/30/2017	8,015	187	N/A	N/A	N/A
3/31/2017	7,672	113	N/A	141	N/A
12/31/2016	7,926	70	N/A	N/A	N/A
9/30/2016	7,948	136	N/A	N/A	N/A
6/30/2016	8,699	481	N/A	N/A	N/A
3/31/2016	8,933	785	N/A	308	N/A
12/31/2015	8,536	1,093	N/A	N/A	N/A
9/30/2015	8,495	1,191	N/A	N/A	N/A
6/30/2015	8,045	1,154	N/A	N/A	N/A
3/31/2015	7,967	1,094	N/A	1,545	N/A
12/31/2014	7,850	950	N/A	N/A	N/A
9/30/2014	7,405	897	N/A	N/A	N/A
6/30/2014	6,914	786	N/A	N/A	N/A

애널리스트 미래 성장 예측

수입 대 저축률: MARKSANS 의 연간 예상 수익 증가율( 23.1% )이 saving rate( 6.7% 보다 높습니다. ).

수익 vs 시장: MARKSANS 의 연간 수익( 23.1% ) Indian 시장( 15.6% 보다 빠르게 성장할 것으로 예상됩니다. 15.6% 연간).

고성장 수익: MARKSANS 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: MARKSANS 의 수익(연간 16.4% ) Indian 시장( 9.4% 보다 빠르게 성장할 것으로 예상됩니다. 9.4% 연간).

고성장 수익: MARKSANS 의 수익(연간 16.4% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: MARKSANS 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 18.6 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/05/18 19:59
장 마감 주가	2025/05/16 00:00
수익	2024/12/31
연간 수익	2024/03/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Marksans Pharma Limited 5 애널리스트 중 2 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Ranjit Kapadia	Centrum Broking Limited
Deepika Murarka	Choice Equity Broking Private Limited
Nitin Agarwal	DAM Capital Advisors

Marksans Pharma 미래 성장

Future 기준 확인 4/6

주요 정보

최근 미래 성장 업데이트

Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price

Price target increased by 26% to ₹330

Recent updates

Should You Be Adding Marksans Pharma (NSE:MARKSANS) To Your Watchlist Today?

Marksans Pharma Limited to Report Q4, 2025 Results on May 19, 2025

Now 25% overvalued

Investor sentiment deteriorates as stock falls 17%

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Now 24% overvalued

Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly

New minor risk - Dividend sustainability

Marksans Pharma Limited's (NSE:MARKSANS) P/E Is On The Mark

Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price

Third quarter 2025 earnings released: EPS: ₹2.31 (vs ₹1.84 in 3Q 2024)

Is Marksans Pharma Limited (NSE:MARKSANS) Expensive For A Reason? A Look At Its Intrinsic Value

Now 25% overvalued

Teva Pharma Facility And US Expansion To Strengthen Future Outlook

Marksans Pharma Limited to Report Nine Months, 2025 Results on Feb 11, 2025

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Marksans Pharma Limited Receives USFDA Approval for Loratadine Tablets USP 10 mg

Price target increased by 26% to ₹330

Second quarter 2025 earnings released: EPS: ₹2.13 (vs ₹1.84 in 2Q 2024)

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Marksans Pharma Limited to Report Q2, 2025 Results on Nov 12, 2024

Marksans Pharma Limited Approves Dividend for the Year Ended March 31, 2024

Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Upcoming dividend of ₹0.60 per share

Insufficient new directors

Now 21% overvalued after recent price rise

Successful Closure of US FDA Inspection At Marksans Pharma's Manufacturing Facility Located At Verna, Goa

Investor sentiment improves as stock rises 17%

New minor risk - Share price stability

Marksans Pharma Limited, Annual General Meeting, Sep 24, 2024

First quarter 2025 earnings released: EPS: ₹1.96 (vs ₹1.52 in 1Q 2024)

Marksans Pharma Limited to Report Q1, 2025 Results on Aug 13, 2024

Now 20% overvalued after recent price rise

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Investor sentiment improves as stock rises 18%

Whole-time Director recently bought ₹6.9m worth of stock

Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Full year 2024 earnings: EPS misses analyst expectations

Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

Marksans Pharma Limited Recommends Final Dividend for the Financial Year 2023-24

Marksans Pharma Limited to Report Q4, 2024 Results on May 30, 2024

Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 23% overvalued after recent price rise

Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

Marksans Pharma Limited to Report Q3, 2024 Results on Feb 13, 2024

We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Investor sentiment improves as stock rises 17%

Second quarter 2024 earnings released: EPS: ₹1.84 (vs ₹1.52 in 2Q 2023)

Marksans Pharma Limited to Report Q2, 2024 Results on Nov 09, 2023

Marksans Pharma Limited Appoints Shailaja Vardhan as an Independent Director

Marksans Pharma Ltd. Receives USFDA Approval for Guaifenesin Extended-Release Tablets

Marksans Pharma Limited Recommends Payment of Dividend for the Financial Year 2022-23

Full year 2023 earnings released: EPS: ₹6.39 (vs ₹4.56 in FY 2022)

Marksans Pharma Limited, Annual General Meeting, Aug 28, 2023

Insufficient new directors

Investor sentiment improves as stock rises 16%

Marksans Pharma Limited Announces That It Has Received Final Approval from the Us Food and Drug Administration for Its Abbreviated New Drug Application for Acetaminophen and Ibuprofen Tablets, 250 Mg/125 Mg

Marksans Pharma Limited Approves Declaration of Dividend for the Financial Year 2022-23, Payable on or After 12 June, 2023

Full year 2023 earnings released: EPS: ₹6.41 (vs ₹4.56 in FY 2022)

Marksans Pharma Limited to Report Q4, 2023 Results on May 30, 2023

Third quarter 2023 earnings released: EPS: ₹1.56 (vs ₹1.20 in 3Q 2022)

Marksans Pharma Limited to Report Q3, 2023 Results on Feb 13, 2023

Marksans Pharma Limited announced that it has received funding from OrbiMed Asia IV Mauritius FVCI Limited

Second quarter 2023 earnings released: EPS: ₹1.52 (vs ₹1.11 in 2Q 2022)

Upcoming dividend of ₹0.25 per share

Full year 2022 earnings released: EPS: ₹4.56 (vs ₹5.83 in FY 2021)

Investor sentiment improved over the past week

Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Full year 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS and revenues miss analyst expectations